Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
BLSM · Why this verdict
Why BlossomHill Therapeutics (BLSM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
BlossomHill is a pre-revenue biotech where insiders bought $25.2M (4.532% of market cap) while the shares sit in capitulation-style selling and the latest quarterly loss far exceeded estimates.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Biotechnology is a binary industry, and quality of 2.9 reflects zero revenue and no margins, so outcomes hinge on clinical results. Suitability rationale | Clinical milestones are reached within 12 months without a new equity raise. | →Stable |
| CounterStrong liquidity (current ratio component 7.6) lowers near-term financing risk. | ||
Seven insider purchases totalling $25,181,900 (4.532% of market cap) and no sales signal strong internal conviction. Insider breakdown | Net insider buying remains positive over the next 12 months. | →Stable |
| CounterInsider buying has not stopped the shares from falling to an RSI of 23. | ||
The latest quarter reported a loss of 8.75 per share against an estimate of 0.77, a very large miss. Earnings | Quarterly losses stabilize and track analyst estimates. | →Stable |
| CounterA single large miss in a pre-revenue biotech may reflect a one-time charge such as a non-cash item. | ||
Momentum at 1.5 shows capitulation risk with RSI 23 below the 200-day average and falling on-balance volume. Momentum breakdown | Momentum recovers above 4.5. | ↑Improving |
| CounterOversold readings can mark a bottom, and insiders are buying into the weakness. | ||
Biotechnology is a binary industry, and quality of 2.9 reflects zero revenue and no margins, so outcomes hinge on clinical results.
→StableSuitability rationale
- Expectation
- Clinical milestones are reached within 12 months without a new equity raise.
CounterStrong liquidity (current ratio component 7.6) lowers near-term financing risk.
Seven insider purchases totalling $25,181,900 (4.532% of market cap) and no sales signal strong internal conviction.
→StableInsider breakdown
- Expectation
- Net insider buying remains positive over the next 12 months.
CounterInsider buying has not stopped the shares from falling to an RSI of 23.
The latest quarter reported a loss of 8.75 per share against an estimate of 0.77, a very large miss.
→StableEarnings
- Expectation
- Quarterly losses stabilize and track analyst estimates.
CounterA single large miss in a pre-revenue biotech may reflect a one-time charge such as a non-cash item.
Momentum at 1.5 shows capitulation risk with RSI 23 below the 200-day average and falling on-balance volume.
↑ImprovingMomentum breakdown
- Expectation
- Momentum recovers above 4.5.
CounterOversold readings can mark a bottom, and insiders are buying into the weakness.
Per-dimension breakdown
Quality
2.9/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.6 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.5 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
Sentiment
8.5/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 10.0 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 115%
Insider
8.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
- ▸Heavy insider buying — $25,181,900 (4.813% of mkt cap)
Peer rank
4.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.8 |
| support resistance | 5.1 |
| 52w position | 1.8 |
Risk (lower is worse)
5.9/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 8.8 |
| volatility | 0.0 |
| debt equity | 8.9 |
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (8)
- MOMENTUM:6.0>=5.5
- ASYMMETRY:5.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:17d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
5.81
Upside
+87.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 48 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Drawdown -41% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 5.81.
The strongest dimensions are Value at 9.0, Sentiment at 8.5, and Insider at 8.5; the weakest are Catalyst at 1.7, Quality at 2.9, and Technical at 3.9. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 5.81 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying
Trip ifNet insider buying over a trailing 90 days falls below $5M from the current $25.2M.
- P2Widening Quarterly Loss
Trip ifQuarterly EPS loss narrows to less than 2.00 per share from the latest 8.75.
- P3Capitulation Momentum
Trip ifMomentum score rises above 4.5 from the current 1.5.
- P4Binary Biotech Risk
Trip ifQuality score rises above 4.0 from the current 2.9.